Introduction to Bioregulatory Medicine
Total Page：16
File Type：pdf, Size：1020Kb
Thieme Verlag Sommer-Druck Smit, Introduction to WN 025912/01/01 11.8.2009 Frau Kurz Feuchtwangen Bioregulatory Medicine TN 147611 Index 161 Index A anaerobiosis theory 129 Arndt-Schulz rule 21–22, 113 anergy, Acidum alpha-ketoglutari- Arnica montana 21–22, 74 acetoacetate 98 cum 89 arthritis 157 acetone 98, 99 anthraquinones 108, 117–118, association-induction theory acetyl coenzyme A 84, 85, 97, 98, 121 134–135 99 antibodies, antigen-specific ATP synthetase 106 oxaloacetate metabolism 26–27 autoimmune diseases 156 101–102 antigen presenting cells (APCs) autologous blood therapies 148, Acidum alpha-ketoglutaricum 23, 25, 70–71 155 88–90 antigens 25, 26 autoregulating systems (ARSs) Acidum cis-aconitum 87–88 antihomotoxic medications 45, 2–12, 13 Acidum citricum 83–87 46–47 base rigidity 9, 10 Acidum fumaricum 92–94 availability 145 bipolar feedback systems 4, 6, Acidum succinicum 90–91 classification 142–143 11, 12, 13, 27 acne 158 dosage 146–147 blood glucose regulation 12, aconitase reaction 88 functiotropic 142–143 13 cis-aconitic acid 87–88 multitargeted interven- blood pressure 12 adaptive immune system 70–73 tions 76–77 body temperature 9–12 adenosine diphosphate (ADP) names 145 closed systems 7 105, 106 organotropic 142–143 cybernetics 4–6 adenosine triphosphate (ATP) potencies 146, 147 definition 2 105, 106, 109–110, 112 quinones 113 fluctuating reality 3 adrenal glands, parabenzoquinone selection 145–147 homeostasis 2, 3–4 affinity 119 tolerability 70 homotoxins 35 adrenaline 54 antihomotoxic treatment immune system 69–70 adrenocorticotropic hormone biopuncture 149–154 inflammation 19–24 (ACTH) 27, 28, 29 catalysts 78, 79–98, 99, interactive 1 aging 100–105 negative feedback systems 4–5 Baryum oxalsuccinicum 92 cell support 78–98, 99, open systems 7 oxidative phosphorylation 100–131 positive feedback systems 4, slowing 111 detoxification 49–69 5–6 agricultural chemicals 52–53, 58 drainage 49–69 rigid 20, 73 alarm stage of stress 30 injection therapies 147–154 set points 3 albumin 31 organ support 131–143 stress-related exhaustion alcohol dehydrogenase pathway oxidative phosphorylation 29–31 58, 59 105–131 top rigidity 8, 9 aldehydes 126–128 planning 146 wave pattern within set point aldosterone 12 special methods 147–154 margins 7–8 allergies, progressive auto-sanguis antioxidants 106 therapy 156 apoptosis 141 Amadori reaction 128 arginine 100–101 amino acids 98, 100 Arndt, Rudolf 21 aus: Smit u.a., Introduction to Bioregulatory Medicine (ISBN 9783131476111) © 2009 Georg Thieme Verlag KG Thieme Verlag Sommer-Druck Smit, Introduction to WN 025912/01/01 11.8.2009 Frau Kurz Feuchtwangen Bioregulatory Medicine TN 147611 Index 162 Index B general excretion infusion cybernetics 4–6 156 cyclo-oxygenase (COX) pathway B-cells 70 Krebs cycle intermediates 78, 20–21 bacteria, symbiotic gut 66–67, 79–80, 104 cyclo-oxygenase 2 (COX-2) inhibi- 76 CD markers 70 tors 21 barium 91–92 CD4+ T-cells 26, 70, 71 cytochrome c oxidase 106 Baryum oxalsuccinicum 91–92 CD8+ T-cells 26, 70 cytochrome c reductase 106 basic combinations 143 cell(s) cytochrome P450 (CYP450) system Bellis perennis 74 cytoskeleton 135 58–59, 67 Berberis-Homaccord 153 embedded 140 cytogenetics 138 Bernard, Claude 3, 4, 131–132 function 3, 4 cytokines 16, 19–20, 73 beta-oxidative path 84, 85 health 140–142 cytoplasm 138 Bier, August 139 interdependence 136 bile 31, 62 matrix 135 bilirubin 32 nonembedded 140 D biopuncture 149–154 nucleus 135, 138 clinical effects 152 permeability 134 defense mechanisms 36 contraindications 154 respiration 111, 111 degenerative joint diseases 156 definition 149 cell concept, new 133–135 dendritic cells 25–26 injection 149–151 cell death 141 desoxycortisol, diurnal techniques 152–154 cell paradigm 137–139 rhythm 29 medications 150 cell support 78–98, 99, 100–131 detoxification 49–69, 146 technical complications 154 cellular phases of disease evolu- “4-S” treatment 68–69 bioregulation, definition 1 tion 38–39, 40–41 liver 159 bipolar feedback systems 4, 6 chemiosmotic mechanism 106 organs 61–69 blood glucose homeostasis 12, chemokines 19 physiology 54, 56–61 13 children, Coenzyme compositum diabetes 83, 96, 97 hypophysis 27 actions 104 dicarbonyl groups 130 thermoregulation 11 cholestasis 159 diets bisphenol A 53 cholesterol 31, 84, 85 carbohydrate-rich 98, 99 blood pressure 12 chondrocytes 14 low-fat 100, 101 blood therapies, autologous 148, chromatin 138 slimming and pyruvate 155 chromosomes 138, 139 use 81–82 blood–brain barrier 58 circulatory disorders 157 disease Bürgi, Emil 46 citric acid 83–87, 97 cell function 3, 4 Bürgi principle 46–47 citric acid cycle see Krebs cycle expression 36 cleansing therapy 146 homotoxicological definition cloning 65 35–36 C closed systems 1, 7 treatment at organ level 141 Coenzyme compositum 103–104 disease evolution 42–43 Calendula officinalis 22 coenzyme Q see ubiquinone cellular phases 38–39, 40–41 cancer, etiopathogenesis colitis 159 dedifferentiation phase 38–39, 112–113, 129 colloids 136 41, 42 Candida albicans 72–73 complement 74 degeneration phase 38–39, Cannon, Walter Bradford 3, 4, complementary medicine, extra- 40–41, 42 132 cellular matrix 16 deposition phase 38–39, 40, carbon dioxide emissions 6 composita 142 42 carbonyl compounds 126, 127 conception, failure 160 disordered progression 43 carbonyl groups 130 connective tissue 136–137 excretion phase 37, 38–39, 42 Cassia 108 corticotrophin-releasing hormone humoral phases 37, 38–39 catalase 67 (CRH) 27, 28 impregnation phase 38–39, catalyst preparation groups cortisol 4–5, 7, 28, 29, 64 40, 42 (CPGs) 46 cortisone 64–65, 76 inflammation phase 37, catalysts 78, 79–98, 99, Crick, Francis 139 38–39, 42 100–105, 142 crystallography 138–139 linear progression 43 aus: Smit u.a., Introduction to Bioregulatory Medicine (ISBN 9783131476111) © 2009 Georg Thieme Verlag KG Thieme Verlag Sommer-Druck Smit, Introduction to WN 025912/01/01 11.8.2009 Frau Kurz Feuchtwangen Bioregulatory Medicine TN 147611 Index Index 163 matrix phases 38–39, 40 F Glyoxal compositum 130 phases 37, 38–39, 40–41 glyoxalase system 127, 128, 129 – regulation/compensation divi- FADH2 106, 109 glyoxalation process 125 128 sion 38–39, 41, 42, 142, 143 fast acetylators 59 glyoxylide 115 disease evolution table (DET) fasting 101 greater defense system 24–33 36–37, 38–39, 40–43, 142 fatigue 95 detoxification in liver 31–33 classification 38–39, 41–42 fats, accumulation 98, 99 neural reflex system 31 therapy schemes 42 feedback systems 1 reticuloendothelial system diurnal rhythm, ACTH 29 feed-forward systems 7 24–27 DNA 138–139 fetus, toxin exposure 58 see also hypothalamus–hypo- dose–response curves 51 fibroblasts 18, 19 physis–suprarenal cortex double helix model 139 fibromyalgia 95, 96 Grifola frondosa (maitake) 128 drainage 49–69 Fishbein, Morris 115 Gripp-Heel 148, 154 Drosera 118 flavin-adenine dinucleotide ground regulation system 14–19, drugs, therapeutic 53 (FAD) 90–91 136–137 drugs of abuse 53 flavin-containing mono-oxidases ground substance 14, 15 (FMOs) 58 gut-associated lymphoid tissue Flemming, Walther 138 (GALT) 74, 76 E fluctuating reality 3 fluid interchange 65–66 Echinacea compositum 148 food additives/preservatives H eczema 158 53–54 elderly people free radical(s) 107, 111, 111 Hahnemann, Samuel 160 Coenzyme compositum free radical scavengers 67 hair 68 actions 103–104 fructosamine 128 health 2 diabetes 96 fumaric acid 92–94 evolution 43 heart disease 158 functiotropic medications heart disease 158 elimination, organs 61–69 142–143 heart rhythm 3 Embden–Meyerhof cycle 112, heartburn 159 128 heavy metals 52, 68 embryogenesis 128, 140 G Helicobacter pylori 159 Engystol 23–24, 74, 76, 77, 148, helminths 72 154 gallbladder 62 hematogenic oxygenation therapy enterohepatic circulation 62 gastrointestinal tract 67, 159 155 environmental toxins 50, 51 gastrulation 140 heme 90, 92 eosinophilic rhinosinusitis 73 general adaptation syndrome Henderson, Lawrence 132 epigenetics 51 (GAS) 29–30 Hepar compositum 153 Euphorbium compositum 148, general excretion infusion 156 hepatic steatosis 83 154 genetic mutations 113 hepatitis 158 excretion infusion 158, 159 genetics 138 hepatocarcinogenesis 92, 93 exhaustion 30, 89 global warming 6 hepatocytes 31, 61–62 extracellular matrix (ECM) 14–19 gluconeogenesis 95, 97, 98, 100 Hepeel 143, 153 cellular health 140–142 glucose histamine 54, 67 detoxification 17, 64–65 blood level regulation 12, 13 homaccords 143, 147 elimination 64–65 liver storage 31, 32 homeopathic substances 74, 76 homeodynamics of fluids glutamic acid 88–90 homeosiniatry 148–149 132–133 glutathione 67 homeostasis 1, 2, 3–4 organ support 131–132, glycation, advanced 123 blood glucose 12, 13 135–137 glycation end products, advanced deregulation by toxins 17–18 terrain concept 131–132 123, 125, 128 inflammation goal 19, 21 transport pathway role 137 glycoaldehyde 126–127, 128 liver function 31 glycogen 32 homing 65 glycolysis 106 homotoxicology glycosaminoglycans 14, 17, 18, 64 applied 73–74, 75, 76 glyoxal 122–125, 129, 130 case histories 146 aus: Smit u.a., Introduction to Bioregulatory Medicine (ISBN 9783131476111) © 2009 Georg Thieme Verlag KG Thieme Verlag Sommer-Druck Smit, Introduction to WN 025912/01/01 11.8.2009 Frau Kurz Feuchtwangen Bioregulatory Medicine TN 147611 Index 164 Index catalysts 78, 79–98, 99, infections, liver role 32–33 kidneys 62–63 100–105 inflammation Koch, William F. 114–115, 132 organ support 131–143 biological objectives 19 Kopaczwewski, Waldislaw 132, oxidative phosphorylation cytokines 19–20 133 105–131 disease evolution phase 37, Krebs,